Immutep Limited has announced the discontinuation of TACTI-004, a pivotal Phase III clinical trial investigating eftilagimod alfa (efti) as a first-line treatment for advanced non-small cell lung cancer (NSCLC). According…
June 2025 marked a month of significant progress in cancer care, as the FDA approved several new therapies and treatment combinations across a range of cancer types. As reported by…
According to a publication from Augusta University, a recent study lung cancer patients receiving chemotherapy provided a possible explanation for some cancers' ability to resist treatment. The research, conducted by…
According to a publication from CURE Today, the US Food and Drug Administration (FDA) recently approved Genentech, Inc's Rozlytrek (generic name entrectinib) for the treatment of cancer patients who have…
NSCLC Non-small cell lung cancer or NSCLC is the most common kind of lung cancer diagnosis. It affects over 2 million people and of those, there's a small group who…
Pfizer has announced that the medicine Xalkori (crizotinib) has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for two potential treatment uses. The full article can be…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
